Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection

Gut

Volumn 64, Issue 3, 2015, Pages 495-503

  Hsu, Yao Chun ^a,b,c   Ho, Hsiu J ^d   Huang, Yen Tsung ^e   Wang, Hsi Hao ^b   Wu, Ming Shiang ^f   Lin, Jaw Town ^g,h   Wu, Chun Ying ^a,d,h,i,j  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b E DA HOSPITAL   (Taiwan)

^c I SHOU UNIVERSITY   (Taiwan)

^d TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^e BROWN UNIVERSITY   (United States)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^h NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

ⁱ NATIONAL YANG MING UNIVERSITY   (Taiwan)

^j NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT PROTEIN; RIBAVIRIN;

ACUTE CORONARY SYNDROME; ADULT; ANTIVIRAL THERAPY; ARTICLE; AUTOIMMUNE DISEASE; BRAIN ISCHEMIA; COHORT ANALYSIS; CONTROLLED STUDY; END STAGE RENAL DISEASE; FEMALE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RISK REDUCTION; TAIWANESE; TREATMENT DURATION; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY FAILURE; COMPLICATION; DRUG COMBINATION; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ADULT; ANTIVIRAL AGENTS; AUTOIMMUNE DISEASES; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HUMANS; INTERFERON-ALPHA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROPORTIONAL HAZARDS MODELS; RECOMBINANT PROTEINS; RIBAVIRIN; STROKE; TREATMENT OUTCOME;

EID: 84922360592     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-308163     Document Type: Article

References (42)

1. Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010; 14:1-21, vii.
2. Perz JF, Armstrong GL, Farrington L.A., et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45:529-38.
3. Gumber SC, Chopra S. Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med 1995; 123:615-20.
4. Agnello V, De Rosa FG. Extrahepatic disease manifestations of HCV infection: some current issues. J Hepatol 2004; 40:341-52.
5. Lee MH, Yang HI, Lu S.N., et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012; 206:469-77.
6. Tsui JI, Vittinghoff E, Shlipak M.G., et al. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med 2007; 167:1271-6.
7. Su FH, Su CT, Chang S.N., et al. Association of hepatitis C virus infection with risk of ESRD: a population-based study. Am J Kidney Dis 2012; 60:553-60.
8. Ishizaka N, Ishizaka Y, Takahashi E., et al. Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. Lancet 2002; 359:133-5.
9. Adinolfi LE, Restivo L, Zampino R., et al. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. Atherosclerosis 2012; 221:496-502.
10. Petta S, Torres D, Fazio G., et al. Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations. Hepatology 2012; 55:1317-23.
11. Lee MH, Yang HI, Wang C.H., et al. Hepatitis C virus infection and increased risk of cerebrovascular disease. Stroke 2010; 41:2894-900.
12. Liao CC, Su TC, Sung F.C., et al. Does hepatitis C virus infection increase risk for stroke? A population-based cohort study. PLoS One 2012; 7:e31527.
13. Agmon-Levin N, Ram M, Barzilai O., et al. Prevalence of hepatitis C serum antibody in autoimmune diseases. J Autoimmun 2009; 32:261-6.
14. European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60:392-420.
15. Fried MW, Shiffman ML, Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-82.
16. Ge D, Fellay J, Thompson A.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
17. Yu ML, Dai CY, Huang J.F., et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007; 56:553-9.
18. Yu ML, Dai CY, Huang J.F., et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008; 47:1884-93.
19. Liu CH, Liu CJ, Lin C.L., et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008; 47:1260-9.
20. van der Meer AJ, Veldt BJ, Feld J.J., et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308:2584-93.
21. Morgan RL, Baack B, Smith B.D., et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013; 158:329-37.
22. Berenguer J, Alvarez-Pellicer J, Martin P.M., et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009; 50:407-13.
23. Berenguer J, Rodriguez E, Miralles P., et al. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus. Clin Infect Dis 2012; 55:728-36.
24. Hsu YC, Lin JT, Ho H.J., et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 2014; 59:1293-302.
25. Cheng CL, Kao YH, Lin S.J., et al. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf 2011; 20:236-42.
26. Wu CY, Chan FK, Wu M.S., et al. Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel. Gastroenterology 2010; 139:1165-71.
27. Wang HH, Hung SY, Sung J.M., et al. Risk of stroke in long-term dialysis patients compared with the general population. Am J Kidney Dis 2014; 63:604-11.
28. Wu CY, Chen YJ, Ho H.J., et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 2012; 308:1906-14.
29. Wu CY, Lin JT, Ho H.J., et al. Association of Nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B-A nationwide cohort study. Gastroenterology 2014; 147:143-151.e5.
30. Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med 2007; 26:734-53.
31. Charlson ME, Pompei P, Ales K.L., et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373-83.
32. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16:1141-54.
33. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. JASA 1999; 94:496-509.
34. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36:S237-44.
35. Pugi A, Bonaiuti R, Maggini V., et al. Safety profile of antiviral medications: a pharmacovigilance study using the Italian spontaneous-reporting database. Am J Health Syst Pharm 2013; 70:1039-46.
36. Feng B, Eknoyan G, Guo Z.S., et al. Effect of interferon-alpha-based antiviral therapy on hepatitis C virus-associated glomerulonephritis: a meta-analysis. Nephrol Dial Transplant 2012; 27:640-6.
37. Arase Y, Suzuki F, Suzuki Y., et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009; 49:739-44.
38. Conjeevaram HS, Wahed AS, Afdhal N, et al. Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. Gastroenterology 2011; 140:469-77.
39. Molleston JP, Mellman W, Narkewicz M.R., et al. Autoantibodies and autoimmune disease during treatment of children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2013; 56:304-10.
40. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006; 55:1350-9.
41. Liang TJ, Ghany MG. Therapy of hepatitis C-back to the future. N Engl J Med 2014; 370:2043-7.
42. Southern DA, Faris PD, Brant R, et al. Kaplan-Meier methods yielded misleading results in competing risk scenarios. J Clin Epidemiol 2006; 59:1110-14.